Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
NCT ID: NCT04407182
Last Updated: 2021-01-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-05-04
Study Completion Date
2020-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus infection.
Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.
A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care and 20 control patients with standard of care.
Treatment duration: 21 days.
Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.
A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care and 20 control patients with standard of care.
Treatment duration: 21 days.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
NCT04701502
Covid19
Respiratory Disease
Immune System
+3 more
COMPLETED
PHASE2
Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip
NCT04980534
Covid19
COVID-19 Pneumonia
COVID-19 Respiratory Infection
+4 more
COMPLETED
NA
Viusid in Adults With Acute Fever of Viral Etiology
NCT01008007
Acute Fever of Viral Etiology
COMPLETED
PHASE2
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19
NCT04551768
COVID19
COMPLETED
PHASE1
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
NCT04523181
Covid-19
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In December 2019, a group of "pneumonia of unknown origin" cases were reported in Wuhan, China. Only a few days later, Chinese health authorities confirmed that this group was associated with the coronavirus and that the disease caused by it was named Coronavirus Disease 2019 (COVID-19) by the WHO. Confirmed by comparative homology analysis, COVID-19 is closely associated with the bat-like severe acute respiratory syndrome (SARS) coronavirus (bat-SL-covzc45 and bat-SL-covzxc21, with 88% identity), but it is a far cry from coronavirus of severe acute respiratory syndrome (SARS-CoV) (about 79%) and coronavirus from respiratory syndrome of the Middle East (MERS-CoV) (about 50%). The National Health Commission of the People's Republic of China reported a total of 77,658 confirmed cases, including 9,162 with serious illnesses and 2,663 deaths as of February 25, 2020.ç
The new pathogen β-coronavirus was initially named as the new coronavirus (2019-nCoV), but on January 12, 2020 the World Health Organization (WHO) named it coronavirus 2019 (COVID-19). Epidemiological reports demonstrated high infectivity from person to person in social, family, and hospital settings. Given this rapid increase in new cases worldwide, the WHO declared a pandemic state 13 The results of a meta-analysis showed that the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). Comorbidities included hypertension, diabetes, respiratory system disease, and cardiovascular disease. For the Chinese Center for Disease Control and Prevention CDC, a suspected or probable case is defined as a case that meets: (1) three clinical criteria or (2) two clinical criteria and one epidemiological criterion. The clinical criteria are: fever; radiographic evidence of pneumonia or acute respiratory distress syndrome; and low or normal white blood cell count or low lymphocyte count. Epidemiological criteria are: living in Wuhan or history of travel to Wuhan within 14 days before the onset of symptoms; contact with patients with fever and symptoms of respiratory infection within 14 days prior to the onset of symptoms; and a link to confirmed cases or groups of suspected cases. Defining a confirmed case, for the first case in a province, is a suspected or probable case with detection of viral nucleic acid at city CDC and provincial CDC. For the second case and all subsequent cases, the definition is a suspected or probable case with detection of nucleic acid from the virus at CDC City. We defined the cases as symptomatic individuals, which could be detected by means of a control temperature across international borders, or who had a disease severity requiring hospital admission, or both, plus travel history to Wuhan. 14 In Ecuador in the city of Guayaquil, the Minister of Health, on February 29, 2020, confirmed the presence of the first "imported" case of Covid-19 in Ecuador. It was an Ecuadorian citizen who arrived from Spain on February 14 at the Guayaquil airport, who had no symptoms. Later days she presented discomfort and fever, reasons for which she was hospitalized and the respective tests were performed for Covid-19 disease, which was positive.
On March 11, 2020, the WHO, the world health organization, officially declares the pandemic caused by the SARS VOC-2 virus and in Ecuador the Emergency Operations Committee is activated, in relation to this committee the following is detailed. The Emergency Operations Committees are components of the Decentralized National Risk Management System, which are responsible for planning and maintaining joint coordination and operation between different levels and functions of the institutions involved in the response and attention to emergencies and disasters in a field territorial defined. On March 12, 2020 two new people tested positive. In total, 19 cases of COVID-19 are registered in Ecuador, the following day the first person died from the coronavirus (COVID-19) occurred in Ecuador. On March 31, 2020, there were 2,240 positive cases for COVID-19, 3,257 suspected, 2,485 discarded from a total of 7,982 samples, 75 confirmed deaths; 61 probable deceased and 54 with hospital discharge. At the beginning of April 2020, the Minister of Public Health, Juan Carlos Zevallos, in a virtual press conference, announced that 100,000 rapid tests and 100,000 PCRs arrived in our country that will serve to expedite the results of the exams for COVID-19.
Until the closing of this project, the records of the MSP indicated that on April 23, 2020, there were 11,183 confirmed cases and 560 people dead. The city of Guayaquil with a population of more than two million inhabitants with the increase in more positive and suspicious cases, became the epicenter of the pandemic at the national level, in this framework, the Teodoro Maldonado Carbo Specialty Hospital located at In the south of the city, it is a third level hospital, since the aforementioned health crisis began with a high influx of patients suspected of covid-19. Current treatment for COVID-19 is supportive, and respiratory failure due to acute respiratory distress syndrome (ARDS) is the leading cause of mortality. Ruan Q et al. Studied the predictors of mortality in a recent retrospective, multicenter study of 150 confirmed cases of COVID-19 in Wuhan, China, including elevated ferritin (mean 1297.6 ng / ml in non-survivors versus 614.0 ng / ml in survivors; p \<0 · 001) and IL-6 (p \<0 · 0001), suggesting that mortality could be due to viral hyperinflammation. There is an urgent need for effective treatment. The current focus has been on the development of new therapies, which include antivirals and vaccines. Accumulated evidence suggests that a subgroup of patients with severe COVID-19 may have cytokine storm syndrome.
Objectives:
Determine the safety and efficacy of Viusid + Asbrip in hospitalized patients with COVID-19 diagnosis.
Keep security through identification, proper and timely management of adverse events and evaluation of biochemical parameters.
Measure efficacy through clinical improvement: evaluation of radiological signs and blood analysis estableshed in this study.
The new pathogen β-coronavirus was initially named as the new coronavirus (2019-nCoV), but on January 12, 2020 the World Health Organization (WHO) named it coronavirus 2019 (COVID-19). Epidemiological reports demonstrated high infectivity from person to person in social, family, and hospital settings. Given this rapid increase in new cases worldwide, the WHO declared a pandemic state 13 The results of a meta-analysis showed that the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). Comorbidities included hypertension, diabetes, respiratory system disease, and cardiovascular disease. For the Chinese Center for Disease Control and Prevention CDC, a suspected or probable case is defined as a case that meets: (1) three clinical criteria or (2) two clinical criteria and one epidemiological criterion. The clinical criteria are: fever; radiographic evidence of pneumonia or acute respiratory distress syndrome; and low or normal white blood cell count or low lymphocyte count. Epidemiological criteria are: living in Wuhan or history of travel to Wuhan within 14 days before the onset of symptoms; contact with patients with fever and symptoms of respiratory infection within 14 days prior to the onset of symptoms; and a link to confirmed cases or groups of suspected cases. Defining a confirmed case, for the first case in a province, is a suspected or probable case with detection of viral nucleic acid at city CDC and provincial CDC. For the second case and all subsequent cases, the definition is a suspected or probable case with detection of nucleic acid from the virus at CDC City. We defined the cases as symptomatic individuals, which could be detected by means of a control temperature across international borders, or who had a disease severity requiring hospital admission, or both, plus travel history to Wuhan. 14 In Ecuador in the city of Guayaquil, the Minister of Health, on February 29, 2020, confirmed the presence of the first "imported" case of Covid-19 in Ecuador. It was an Ecuadorian citizen who arrived from Spain on February 14 at the Guayaquil airport, who had no symptoms. Later days she presented discomfort and fever, reasons for which she was hospitalized and the respective tests were performed for Covid-19 disease, which was positive.
On March 11, 2020, the WHO, the world health organization, officially declares the pandemic caused by the SARS VOC-2 virus and in Ecuador the Emergency Operations Committee is activated, in relation to this committee the following is detailed. The Emergency Operations Committees are components of the Decentralized National Risk Management System, which are responsible for planning and maintaining joint coordination and operation between different levels and functions of the institutions involved in the response and attention to emergencies and disasters in a field territorial defined. On March 12, 2020 two new people tested positive. In total, 19 cases of COVID-19 are registered in Ecuador, the following day the first person died from the coronavirus (COVID-19) occurred in Ecuador. On March 31, 2020, there were 2,240 positive cases for COVID-19, 3,257 suspected, 2,485 discarded from a total of 7,982 samples, 75 confirmed deaths; 61 probable deceased and 54 with hospital discharge. At the beginning of April 2020, the Minister of Public Health, Juan Carlos Zevallos, in a virtual press conference, announced that 100,000 rapid tests and 100,000 PCRs arrived in our country that will serve to expedite the results of the exams for COVID-19.
Until the closing of this project, the records of the MSP indicated that on April 23, 2020, there were 11,183 confirmed cases and 560 people dead. The city of Guayaquil with a population of more than two million inhabitants with the increase in more positive and suspicious cases, became the epicenter of the pandemic at the national level, in this framework, the Teodoro Maldonado Carbo Specialty Hospital located at In the south of the city, it is a third level hospital, since the aforementioned health crisis began with a high influx of patients suspected of covid-19. Current treatment for COVID-19 is supportive, and respiratory failure due to acute respiratory distress syndrome (ARDS) is the leading cause of mortality. Ruan Q et al. Studied the predictors of mortality in a recent retrospective, multicenter study of 150 confirmed cases of COVID-19 in Wuhan, China, including elevated ferritin (mean 1297.6 ng / ml in non-survivors versus 614.0 ng / ml in survivors; p \<0 · 001) and IL-6 (p \<0 · 0001), suggesting that mortality could be due to viral hyperinflammation. There is an urgent need for effective treatment. The current focus has been on the development of new therapies, which include antivirals and vaccines. Accumulated evidence suggests that a subgroup of patients with severe COVID-19 may have cytokine storm syndrome.
Objectives:
Determine the safety and efficacy of Viusid + Asbrip in hospitalized patients with COVID-19 diagnosis.
Keep security through identification, proper and timely management of adverse events and evaluation of biochemical parameters.
Measure efficacy through clinical improvement: evaluation of radiological signs and blood analysis estableshed in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Covid-19
Sars-CoV2
Diabete Mellitus
Cardiopathy
Pulmonary Disease
Renal Disease
Liver Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
SUPPORTIVE_CARE
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Viusid Plus Asbrip
Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.
A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care.
Treatment duration: 21 days.
Group Type
EXPERIMENTAL
Viusid and Asbrip
Intervention Type
DIETARY_SUPPLEMENT
Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.
Treatment duration: 21 days.
Control
A total of 60 subjects will be randomized 2: 1 in this study. 20 Control patients will be assigned to standard of care.
Treatment duration: 21 days.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Viusid and Asbrip
Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.
Treatment duration: 21 days.
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Population over 18 years of age up to 70, sample size 30.
* Subjects with mild to moderate\* symptoms of respiratory illness caused by 2019 coronavirus infection as defined below: Mild disease (uncomplicated):
* Diagnosed with COVID-19 by a standardized RT-PCR assay and Mild symptoms, such as fever, runny nose, mild cough, sore throat, malaise, headache, muscle pain, or discomfort, but no shortness of breath and No signs of more serious lower airway disease.
* RR \<20, HR \<90, oxygen saturation (pulse oximetry)\> 93% in ambient air.
\*Moderate illness:
* Diagnosed with COVID-19 by a standardized RT-PCR assay and
* In addition to the above symptoms, more significant lower respiratory symptoms, including difficulty breathing (at rest or with exertion) or
* Signs of moderate pneumonia, including RR ≥ 20 but \<30, HR ≥ 90 but less than 125, oxygen saturation (pulse oximetry)\> 93% in ambient air, and
* If available, X-ray or computed tomography-based lung infiltrates \<50% present 3. 12-lead ECG at rest clinically normal at the screening visit or, if abnormal, not considered clinically significant by the lead investigator.
4\. The subject (or legally authorized representative) provides her informed written consent before starting any study procedure.
5\. Understand and agree to comply with planned study procedures. 6. Women of childbearing potential must agree to use at least one medically accepted method of contraception (eg, barrier contraceptives \[condom or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combined oral contraceptives, transdermal patches or rings) \] or intrauterine devices) for the duration of the study.
* Subjects with mild to moderate\* symptoms of respiratory illness caused by 2019 coronavirus infection as defined below: Mild disease (uncomplicated):
* Diagnosed with COVID-19 by a standardized RT-PCR assay and Mild symptoms, such as fever, runny nose, mild cough, sore throat, malaise, headache, muscle pain, or discomfort, but no shortness of breath and No signs of more serious lower airway disease.
* RR \<20, HR \<90, oxygen saturation (pulse oximetry)\> 93% in ambient air.
\*Moderate illness:
* Diagnosed with COVID-19 by a standardized RT-PCR assay and
* In addition to the above symptoms, more significant lower respiratory symptoms, including difficulty breathing (at rest or with exertion) or
* Signs of moderate pneumonia, including RR ≥ 20 but \<30, HR ≥ 90 but less than 125, oxygen saturation (pulse oximetry)\> 93% in ambient air, and
* If available, X-ray or computed tomography-based lung infiltrates \<50% present 3. 12-lead ECG at rest clinically normal at the screening visit or, if abnormal, not considered clinically significant by the lead investigator.
4\. The subject (or legally authorized representative) provides her informed written consent before starting any study procedure.
5\. Understand and agree to comply with planned study procedures. 6. Women of childbearing potential must agree to use at least one medically accepted method of contraception (eg, barrier contraceptives \[condom or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combined oral contraceptives, transdermal patches or rings) \] or intrauterine devices) for the duration of the study.
Exclusion Criteria
* None
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catalysis SL
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Especialidades Dr. Teodoro Maldonado Carbo
Guayaquil, , Ecuador
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Ecuador
References
Explore related publications, articles, or registry entries linked to this study.
Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020 Feb;91:264-266. doi: 10.1016/j.ijid.2020.01.009. Epub 2020 Jan 14. No abstract available.
Reference Type
BACKGROUND
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
Reference Type
BACKGROUND
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
Reference Type
BACKGROUND
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26.
Reference Type
BACKGROUND
Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020 Feb 29;395(10225):689-697. doi: 10.1016/S0140-6736(20)30260-9. Epub 2020 Jan 31.
Reference Type
BACKGROUND
Spina S, Marrazzo F, Migliari M, Stucchi R, Sforza A, Fumagalli R. The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy. Lancet. 2020 Mar 14;395(10227):e49-e50. doi: 10.1016/S0140-6736(20)30493-1. Epub 2020 Feb 28. No abstract available.
Reference Type
BACKGROUND
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16. No abstract available.
Reference Type
BACKGROUND
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3. No abstract available.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IESS-HTMC-JUTD-2020-0305-M
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
NCT04575597
COMPLETED
PHASE2/PHASE3
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2
NCT04356677
WITHDRAWN
PHASE1
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
NCT04405739
COMPLETED
PHASE2
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
NCT04405570
COMPLETED
PHASE2
Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients
NCT04768179
UNKNOWN
PHASE2/PHASE3
Losmapimod Safety and Efficacy in COVID-19
NCT04511819
TERMINATED
PHASE3
Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
NCT04596085
COMPLETED
NA
Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit
NCT06008457
COMPLETED
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
NCT04575584
TERMINATED
PHASE2/PHASE3
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
NCT04261907
TERMINATED
NA
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700
RECRUITING
PHASE3
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
NCT04842331
WITHDRAWN
PHASE2/PHASE3
Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19
NCT04594343
COMPLETED
PHASE2
Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient
NCT04595136
UNKNOWN
PHASE1/PHASE2
Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
NCT06437210
COMPLETED
NA
Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
NCT04532931
COMPLETED
PHASE2
Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)
NCT04480138
TERMINATED
PHASE2
Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19
NCT04424901
TERMINATED
PHASE2
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
NCT04802408
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19
NCT04460183
COMPLETED
PHASE2/PHASE3
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
NCT04535167
COMPLETED
PHASE1
Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)
NCT04608214
COMPLETED
PHASE2
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
NCT04405999
COMPLETED
PHASE4
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients
NCT05596045
WITHDRAWN
PHASE1
A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19
NCT04522830
COMPLETED
PHASE2